Cytokinetics Faces Critical FDA Decision and Financial Pressure

Substantial Cash Reserves Amid Deepening Losses

The biotechnology firm Cytokinetics is navigating a period of extreme uncertainty, with two pivotal December events poised to determine its future trajectory. As the company awaits a regulatory verdict on its lead drug candidate, aficamten, shareholders are growing increasingly concerned about its accelerating cash consumption. The situation represents a dramatic race against the clock.

Cytokinetics reported a troubling financial performance for the third quarter of 2025. The company’s net loss surged to $306.2 million, equating to a per-share loss of $2.55 and falling significantly short of analyst projections. A substantial portion of this loss, $121.2 million, stemmed from expenses related to a debt conversion transaction.